July 19, 2017 Price forecast | 2 weeks: 6.73% | 1 month: 7.58% | 3 months: 7.51%


CYCC stock forecast

Our latest prediction for Cyclacel Pharmaceuticals, Inc.'s stock price was made on the July 19, 2017 when the stock price was at 1.75$.

In the short term (2weeks), CYCC's stock price should outperform the market by 6.73%. During that period the price should oscillate between -11.17% and +26.68%.

In the medium term (3months), CYCC's stock price should outperform the market by 7.51%. During that period the price should oscillate between -23.45% and +60.76%.

Create a solid portfolio with CYCC

Add CYCC to your portfolio and optimize it!


About Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

At the moment the company doesn't generate any revenue.

On its last earning announcement, the company reported a loss of -0.34$ per share.

The book value per share is 1.55$

Cyclacel Pharmaceuticals, Inc. website


Three months stock forecastJuly 19, 2017


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
- - -9M - -7M -0.34 - - 12M 1.55 -7M - -7M